Business

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors’ appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors. “Karen has earned the full co

articleArgenx SeMay 6, 20263/company/argenx-se/news/argenx-announces-results-of-annual-general-meeting-and-board-of-directors-appointment-of-karen-massey-as-chief-executive-officer
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

About this update from Argenx Se

[{"type":"image","alt":"argenx SE","displaySize":"","headline":null,"caption":"argenx SE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vn6RW8oK.55yql.o3A46Yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNg--/https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119","width":300,"height":97},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/vn6RW8oK.55yql.o3A46Yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNg--/https://media.zenfs.com/en/globenewswire.com/f35a3a919b58945aa6a1a93a9b760119","width":300,"height":97}},"lazy":false},{"type":"text","content":"Leadership transition marks next evolution of growth","length":52,"tagName":"p"},{"type":"text","content":"May 6, 2026","length":11,"tagName":"p"},{"type":"text","content":"Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors’ appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors.","length":409,"tagName":"p"},{"type":"text","content":"“Karen has earned the full confidence of the Board of Directors and our shareholders,” said Tim Van Hauwermeiren, Chair of the Board of Directors. “She is a proven leader who has played a central role in shaping argenx’s execution and long-term growth strategy. Karen leads with our responsibility to patients, the argenx culture, and a vision to continue to build our pipeline. I look forward to supporting Karen and the leadership team as argenx enters its next phase of growth.”","length":481,"tagName":"p"},{"type":"text","content":"Karen Massey joined argenx in March 2023 as Chief Operating Officer and will succeed Tim Van Hauwermeiren, who co-founded argenx and has served as Chief Executive Officer since 2008. Her appointment by the Board of Directors as CEO follows shareholder approval of her appointment as executive director of the Board of Directors. The Board of Directors also appointed Tim Van Hauwermeiren as Chairperson of the Board of Directors, effective immediately, following his appo...

More updates from Argenx Se

the Board of DirectorsKaren MasseyTim Van Hauwermeirenautoimmune diseasesChief Executive Officer